Drug Profile
Fimasartan/rosuvastatin - Boryung Pharmaceutical
Alternative Names: BKC-003; Rosuvastatin/fimasartan; TuveroLatest Information Update: 08 Jul 2019
Price :
$50
*
At a glance
- Originator Boryung Pharmaceutical
- Class Antihyperlipidaemics; Antihypertensives; Fluorobenzenes; Pyrimidines; Pyrimidinones; Small molecules; Sulfonamides
- Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Dyslipidaemias; Hypertension
Most Recent Events
- 08 Jul 2019 Chemical structure information added
- 28 Apr 2019 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in USA (PO, Tablet)
- 31 Aug 2016 Preregistration for Dyslipidaemias in South Korea (PO) (Boryung pharmaceuticals pipeline, August 2016)